Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...

Please provide your email address to receive an email when new articles are posted on . Men with severe hypogonadism reported improved sexual function after testosterone replacement therapy with ...

Bayer has found a buyer for its hypogonadism drug Nebido but is keeping it in Germany as Grünenthal picks up its global rights for 500 million euros ($500 million). The treatment, which is the lone ...

Indevus Pharmaceuticals Says Testosterone Therapy Trial Meets Primary Goal LEXINGTON, Mass., June 7 -- Indevus Pharmaceuticals, Inc. today announced final results from its Phase III pharmacokinetic ...

Grünenthal acquires Nebido TM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023. Nebido TM is the gold standard for the treatment ...

Bayer's venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business. Grünenthal is paying up ...

"Testosterone deficiency affects one in six men over 50 years 1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. "With the completion of this deal, we can now work to bring ...

LEXINGTON, Mass.--(BUSINESS WIRE)--July 29, 2005--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has licensed exclusive U.S. rights from Schering AG, Germany (NYSE: SHR) to ...

AACHEN, Germany, July 14, 2022 /PRNewswire/ -- Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire Nebido TM, the ...

BERLIN (Reuters) - Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN ...

BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...

Grünenthal acquires Nebido TM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023. Nebido TM is the gold standard for the treatment ...